DIFFERENCES IN GUIDANCE ON PRO EVIDENTIARY REQUIREMENTS ACROSS KEY EUROPEAN HTA AGENCIES

被引：0
|
作者：
Chassany, O. [1 ]
van Engen, A. [2 ]
Lai, L. [3 ]
Borhade, K. [4 ]
Ravi, M. [4 ]
Harnett, J. [5 ]
Chen, C., I [5 ]
Quek, R. G. W. [5 ]
机构：
[1] Univ Paris, Patient Reported Outcomes Unit, Paris 75, France
[2] IQVIA, Amsterdam, Netherlands
[3] IQVIA, Reading, Berks, England
[4] IQVIA, Bangalore, Karnataka, India
[5] Regeneron Pharmaceut, Tarrytown, NY USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HTA9
引用
收藏
页码：S505 / S505
页数：1
相关论文
共 18 条
  • [1] Differences In HTA Acceptance Rates Across Disease Areas: A Comparison Between Four HTA Agencies
    Vadlamudi, N. K.
    Griffiths, E. A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A287 - A287
  • [2] DIFFERENCES AND SIMILARITIES IN THE LEVEL OF EVIDENTIARY REQUIREMENTS REQUIRED FOR ORPHAN DRUGS DURING HTA APPRAISAL IN CEE COUNTRIES
    Djambazov, S.
    Filipov, A.
    Dacheva, A.
    Vutova, Y.
    Vekov, T.
    [J]. VALUE IN HEALTH, 2020, 23 : S665 - S665
  • [3] A call to action to harmonize patient-reported outcomes evidence requirements across key European HTA bodies in oncology
    Chassany, Olivier
    van Engen, Anke
    Lai, Livia
    Borhade, Kunal
    Ravi, Manukiran
    Harnett, James
    Chen, Chieh-, I
    Quek, Ruben Gw
    [J]. FUTURE ONCOLOGY, 2022, 18 (29) : 3323 - 3334
  • [4] SIMILARITIES AND DIFFERENCES IN EUROPEAN HTA EVIDENCE REQUIREMENTS: ONE FOR ALL OR ONE FOR NONE?
    Mordin, M.
    Fernandez, M. M.
    Pearson, I
    Copley-Merriman, C.
    McBride, D.
    [J]. VALUE IN HEALTH, 2018, 21 : S7 - S7
  • [5] TRENDS AND KEY DECISION DRIVERS FOR REJECTING AN ORPHAN DRUG SUBMISSION ACROSS FIVE DIFFERENT HTA AGENCIES
    Mardiguian, S.
    Stefanidou, M.
    Sheppard, F.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A438 - A438
  • [6] REVIEW OF HEALTH TECHNOLOGY ASSESSMENT (HTA) REQUIREMENTS FOR RARE DISEASES ACROSS EUROPEAN COUNTRIES
    Sanchez, Garcia J. J.
    Sattar, S.
    Hill, C. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A491 - A491
  • [7] AN ANALYSIS OF ULTRA-ORPHAN INITIAL ASSESSMENTS IN SCOTLAND COMPARED WITH OTHER KEY EUROPEAN HTA AGENCIES
    Foster, D.
    Walker, S.
    Phalguni, A.
    Jones, G.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S178 - S178
  • [8] Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions
    Wang, Ting
    McAuslane, Neil
    Liberti, Lawrence
    Leufkens, Hubert
    Hovels, Anke
    [J]. VALUE IN HEALTH, 2018, 21 (06) : 707 - 714
  • [9] DO WE NEED TO MIND THE GAP: AN ANALYSIS OF THE EVIDENCE BASE DIFFERENCES AND ALIGNMENT ACROSS REGULATOR AND HTA AGENCIES
    Harrison, K.
    O'Rourke, D.
    Jonsson, P.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S21 - S22
  • [10] DIFFERENCES AND SIMILARITIES IN THE LEVEL OF EVIDENTIARY REQUIREMENTS REQUIRED FOR ORPHAN DRUGS DURING HTA APPRAISAL IN BULGARIA, FRANCE, GERMANY, SWEDEN, AND THE UK: A COMPARATIVE ANALYSIS
    Djambazov, S.
    Filipov, A.
    Dacheva, A.
    Vutova, Y.
    Vekov, T.
    [J]. VALUE IN HEALTH, 2020, 23 : S672 - S672
12